Search Within

GDMT, Medicine

Formats
  1. Journal Article (935)
  2. Meeting Abstract (836)
  3. Review (49)
  4. Book Section (38)
  5. Editorial (30)
  6. Guidelines (19)
  7. Correspondence (7)
  8. Research Letter (1)
Groups
  1. Gynecology Disease Management Team (1915)
  2. Department of Medicine (1904)
  3. Solid Tumor Oncology Division (1904)
  4. Gynecologic Medicine Service (1864)
  5. Surgery (585)
  6. GDMT, Surgery (467)

More Groups

People
  1. Carol Aghajanian (616)
  2. Martee Hensley (290)
  3. Nadeem Abu-Rustum (281)
  4. Roisin O'Cearbhaill (275)
  5. Vicky Makker (270)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (78)
  2. 2024 (159)
  3. 2023 (165)
  4. 2022 (196)
  5. 2021 (146)
  6. 2020 (173)

More Years

Publications
  1. Journal of Clinical Oncology (421)
  2. Gynecologic Oncology (419)
  3. International Journal of Gynecological Cancer (156)
  4. Annals of Oncology (107)
  5. Clinical Cancer Research (65)
  6. Cancer (37)

More Publications

Publishers
  1. American Society of Clinical Oncology (453)
  2. Elsevier B.V. (443)
  3. Lippincott Williams & Wilkins (181)
  4. American Association for Cancer Research (141)
  5. Oxford University Press (130)
  6. Elsevier Inc. (83)

More Publishers

Results (1915)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinicopathologic and molecular features associated with response to anti-HER2 therapy in endometrial cancer
    Meeting Abstract

    Shen, S.; Ma, W.; Zhou, Q.; Iasonos, A.; Zhang, Y.; Ross, D. S.; Makker, V.; Chui, M. H.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib plus dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC)
    Meeting Abstract

    Randall, L. M.; O'Malley, D. M.; Monk, B. J.; Coleman, R. L.; Gaillard, S.; Adams, S. F.; Duska, L. R.; Cappuccini, F.; Dalton, H.; Holloway, R. W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO)
    Meeting Abstract

    Patel, M. R.; Makker, V.; Oaknin, A.; Pignata, S.; Backes, F. J.; Martin, A. G.; Eskander, R. N.; Pothuri, B.; Richardson, D. L.; Secord, A. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRĪ±) expression: Characterization of antitumor activity in the SORAYA study
    Meeting Abstract

    Matulonis, U. A.; Oaknin, A.; Pignata, S.; denys, H.; Colombo, N.; Van Gorp, T.; Konner, J. A.; Romeo, M.; Harter, P.; Murphy, C. G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Cell-free DNA analysis as a molecular tool to monitor response to immune checkpoint inhibition in endometrial cancer
    Meeting Abstract

    Manning-Geist, B.; Patel, J. A. A.; Marra, A.; Da Cruz Paula, A.; Hanlon, E. J.; Abu-Rustum, N.; Shah, R. H.; Berger, M. F.; Hensley, M. L.; Zamarin, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775
    Meeting Abstract

    Makker, V.; Colombo, N.; Santin, A.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Ray-Coquard, I. L.; Kim, Y. M.; Guerra, E. M.; Huang, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification
    Meeting Abstract

    Makker, V.; Perez-Fidalgo, J. A.; Bergamini, A.; Spitz, D. L.; Van Gorp, T.; Sehouli, J.; Klat, J.; Perri, T.; Oza, A. M.; Hogdall, E. V. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205
    Meeting Abstract

    Lorusso, D.; Vergote, I.; O'Cearbhaill, R. E.; Westermann, A. M.; Banerjee, S. N.; Van Nieuwenhuysen, E.; Iglesias, D. A.; Collins, D. C.; Cibula, D.; Madsen, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer
    Meeting Abstract

    Lukashchuk, N.; Armenia, J.; Tobalina, L.; Carr, T. H.; Milenkova, T.; Liu, Y. L.; Penson, R. T.; Robson, M. E.; Harrington, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save